Financials data is unavailable for this security.
View more
Year on year Fate Therapeutics Inc 's revenues fell -78.55% from 63.53m to 13.63m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 160.93m to a larger loss of 186.26m.
| Gross margin | -- |
|---|---|
| Net profit margin | -2,187.11% |
| Operating margin | -2,448.24% |
| Return on assets | -37.23% |
|---|---|
| Return on equity | -52.35% |
| Return on investment | -40.38% |
More ▼
Cash flow in USDView more
In 2024, cash reserves at Fate Therapeutics Inc fell by 10.76m. Cash Flow from Financing totalled 99.89m or 732.83% of revenues. In addition the company used 122.87m for operations while cash from investing totalled 12.22m.
| Cash flow per share | -1.19 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.03 |
|---|---|
| Tangible book value per share | 2.03 |
More ▼
Balance sheet in USDView more
| Current ratio | 7.87 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
